These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38356106)

  • 41. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
    Yu T; Padula WV; Yieh L; Gong CL
    Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
    Amand C; Tong S; Kieffer A; Kyaw MH
    BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.
    Carroll KN; Gebretsadik T; Escobar GJ; Wu P; Li SX; Walsh EM; Mitchel E; Sloan CD; Dupont WD; Hartert TV
    J Allergy Clin Immunol; 2017 Jan; 139(1):66-71.e3. PubMed ID: 27212083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Rainisch G; Adhikari B; Meltzer MI; Langley G
    Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
    Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina.
    Dvorkin J; Sosa E; Vodicka E; Baral R; Sancilio A; Dueñas K; Rodriguez A; Rojas-Roque C; Carruitero PB; Polack FP; Pecenka C; Libster R; Caballero MT
    BMC Public Health; 2024 Feb; 24(1):427. PubMed ID: 38336643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
    Wang X; Li Y; Shi T; Bont LJ; Chu HY; Zar HJ; Wahi-Singh B; Ma Y; Cong B; Sharland E; Riley RD; Deng J; Figueras-Aloy J; Heikkinen T; Jones MH; Liese JG; Markić J; Mejias A; Nunes MC; Resch B; Satav A; Yeo KT; Simões EAF; Nair H; ;
    Lancet; 2024 Mar; 403(10433):1241-1253. PubMed ID: 38367641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus.
    van Wijhe M; Johannesen CK; Simonsen L; Jørgensen IM; ; Fischer TK
    J Infect Dis; 2022 Aug; 226(Suppl 1):S55-S62. PubMed ID: 35426942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic.
    Alkharsah KR
    Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
    Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
    Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis.
    Brunwasser SM; Snyder BM; Driscoll AJ; Fell DB; Savitz DA; Feikin DR; Skidmore B; Bhat N; Bont LJ; Dupont WD; Wu P; Gebretsadik T; Holt PG; Zar HJ; Ortiz JR; Hartert TV
    Lancet Respir Med; 2020 Aug; 8(8):795-806. PubMed ID: 32763206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.